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find that epithelial NLRX1 protects
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cancer. In the epithelium, NLRX1 controls
the expression of intestinal wound
healing factors following injury and
inhibits the proliferative action of TNF.
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The mitochondrial Nod-like receptor protein NLRX1
protects against colorectal tumorigenesis through
mechanisms that remain unclear. Using mice with
an intestinal epithelial cells (IEC)-specific deletion
of Nlrx1, we find that NLRX1 provides an IEC-in-
trinsic protection against colitis-associated carcino-
genesis in the colon. These Nlrx1 mutant mice have
increased expression of Tnf, Egf, and Tgfb1, three
factors essential for wound healing, as well as
increased epithelial proliferation during the epithe-
lial regeneration phase following injury triggered
by dextran sodium sulfate. In primary intestinal or-
ganoids lacking Nlrx1, stimulation with TNF resulted
in exacerbated proliferation and expression of the
intestinal stem cell markers Olfm4 andMyb. This hy-
per-proliferation response was associated with
increased activation of Akt and NF-kB pathways in
response to TNF stimulation. Together, these re-
sults identify NLRX1 as a suppressor of colonic
tumorigenesis that acts by controlling epithelial pro-
liferation in the intestine during the regeneration
phase following mucosal injury.
INTRODUCTION
NLRX1 is a member of the Nod-like receptor (NLR) family of
intracellular sensors of danger-associated molecular patterns
(DAMPs) and microbial-associated molecular patterns
(MAMPs) that function in innate immunity (Philpott et al.,
2014). In contrast to other members of the NLR family,
NLRX1 possesses an N-terminal addressing sequence that tar-
gets the protein to the mitochondrial matrix (Arnoult et al.,2576 Cell Reports 14, 2576–2586, March 22, 2016 ª2016 The Author2009). The exact function of NLRX1 has remained poorly un-
derstood. It was proposed to act as a negative regulator of
antiviral immunity through interaction with the protein MAVS
(Moore et al., 2008), but these findings were not reproduced
by other groups (Jaworska et al., 2014; Rebsamen et al.,
2011; Soares et al., 2013). Overexpression of NLRX1 was
also shown to regulate the formation of reactive oxygen spe-
cies (ROS) by mitochondria (Tattoli et al., 2008). Further support
for this observation was obtained in mouse embryonic fibro-
blasts (MEFs) from Nlrx1/ mice, which displayed blunted
tonic levels of ROS in resting condition as compared to wild-
type (WT) MEFs (Soares et al., 2014).
NLRX1 was also shown to inhibit inflammatory pathways trig-
gered by lipopolysaccharide (Allen et al., 2011; Xia et al., 2011).
Moreover, Nlrx1/ mice display increased cerebral inflamma-
tion in a model of experimental autoimmune encephalopathy (Ei-
tas et al., 2014), higher lung inflammation in a model of cigarette
smoke-induced chronic obstructive pulmonary disease (Kang
et al., 2015), and enhanced intestinal inflammation in a colitis
model induced by dextran sodium sulfate (DSS) (Soares et al.,
2014). However, the underlying mechanism through which
NLRX1 controls inflammation in these various models remains
unclear.
Recently, findings from several groups have identified a role
for NLRX1 in the control of cell death in various cellular sys-
tems (Imbeault et al., 2014; Jaworska et al., 2014; Singh
et al., 2015; Soares et al., 2014). However, it remains unclear
if the effect of NLRX1 on ROS or cell death signaling is direct
or whether it is a consequence of an overarching function of
the protein in the mitochondria that remains to be identified.
In support of the latter hypothesis, it must be noted that
NLRX1 expression is significantly repressed by glucose starva-
tion (Soares et al., 2014); in addition, NLRX1 silencing is suffi-
cient to upregulate the basal activities of complex I and III of
the mitochondrial respiratory chain (Singh et al., 2015), sug-
gesting that NLRX1 may act to tie mitochondrial oxidatives
phosphorylation (Oxphos) activity to the cellular availability of
glucose. As such, NLRX1 could play a role as a tumor
suppressor by inhibiting mitochondrial Oxphos-dependent
generation of ATP in conditions of nutrient sufficiency. This
hypothesis is supported by several lines of evidence. First,
NLRX1 expression is strongly reduced by SV40- or Ras-
dependent transformation in a genome-wide study (Danielsson
et al., 2013), a result that we confirmed by analyzing Nlrx1
expression by qPCRand western blotting in primary versus in
SV40-transformed MEFs (Soares et al., 2014). Second, we
recently demonstrated that Nlrx1/ mice display increased
susceptibility to tumorigenesis in a model of colitis-associated
colorectal cancer triggered by injection of azoxymethane
(AOM) followed by three cycles of oral administration of DSS
in drinking water (Soares et al., 2014). Finally, Singh et al.
(2015) demonstrated that NLRX1 expression decreases tumor-
igenic and migration properties of MCF-7 cells in vitro and the
tumorigenic potential of colon cancer RKO cells in vivo using a
xenograft model in nude mice.
While the critical role of NLRX1 in tumorigenesis is increasingly
appreciated, the underlying mechanism remains unclear. In the
AOM/DSS model of colorectal cancer, it is well established
that inflammation is a major driver of tumor progression, as
DSS administration strongly accelerates pathogenesis as
compared to injection of AOM alone (Rosenberg et al., 2009).
Because DSS-induced inflammation is increased in animals
lacking Nlrx1 (Soares et al., 2014), the enhanced tumor burden
observed in Nlrx1/ in the AOM/DSS model as compared to
WTmice could be caused by uncontrolled inflammation. Alterna-
tively, NLRX1’s proposed role in the control of apoptosis and
mitochondrial respiration, as well as its transcriptional regulation
by glucose levels and during cellular transformation, argue for a
cell intrinsic effect of NLRX1 on tumorigenesis. In order to delin-
eate the exact mechanism through which NLRX1 protects
against colorectal cancer, we generated mice lacking Nlrx1
only within the intestinal epithelium. Our results demonstrated
an epithelial-intrinsic role of NLRX1 in the control of colitis-asso-
ciated tumorigenesis. We present evidence that NLRX1 played
its protective role by inhibiting TNF-induced intestinal epithelial
cell (IEC) proliferation, which occurs during the healing phase
post-colitis.
RESULTS
Generation and Analysis of Mice Lacking Nlrx1 in the
Intestinal Epithelium
C57Bl/6 mice with insertion of LoxP sites flanking Exon 3 of
Nlrx1 (Nlrx1fl/fl hereafter) have been described previously
(Soares et al., 2013). We crossed these mice with transgenic
C57Bl/6 mice expressing the Cre recombinase under the Villin
gene promoter in order to excise Nlrx1 specifically in IECs
(Figure S1A). Nlrx1/, WT, Nlrx1fl/fl mice as well as mice with
homozygous deletion of Nlrx1 in IECs (Nlrx1DIEC thereafter)
were analyzed for NLRX1 expression in the spleen and the in-
testinal mucosa by western blotting (Figure 1A). As expected,
only Nlrx1/ mice lost immunoreactivity for NLRX1 in the
spleen. In intestinal mucosal samples of Nlrx1DIEC mice,
NLRX1 expression was absent from the IEC fraction, but notCellthe remaining lamina propria fraction, indicating that Nlrx1 dele-
tion was specific to the IEC population. We also noted that
NLRX1 expression in the spleen and the lamina propria was
similar between WT and Nlrx1fl/fl mice (Figure 1A), thus showing
that LoxP sites insertion in the Nlrx1 locus had no overall effect
on Nlrx1 expression.
Next, we aimed to determine if Nlrx1DIEC mice had intestinal
defects in resting conditions. Importantly, for these experiments
and the ones described in the rest of this study, Nlrx1fl/fl and
Nlrx1DIEC mice were littermates from Nlrx1fl/fl3Nlrx1DIEC mice
crosses. Histology of the colon (Figure 1B) revealed normal crypt
architecture in Nlrx1DIEC mice and no signs of inflammation. IEC
proliferation, as assessed by Ki-67 staining (Figures 1C and 1D)
and analysis of Cyclin D1 and Cyclin B1 expression by quantita-
tive (q)PCR, was also unaffected by Nlrx1 deletion (Figure 1D).
Immunofluorescence using an antibody against chromogranin
A revealed a normal number of enteroendocrine cells in the
colonic epithelium of Nlrx1DIEC mice (Figures 1E and S1C) and
expression ofChga,Gcg, andCck, threemarkers of enteroendo-
crine cells, was also normal in the colon of Nlrx1DIEC mice (Fig-
ure 1F). Alcian Blue-Periodic acid-Schiff (AB-PAS) staining and
immunofluorescence staining using an antibody against Muc2
also showed that goblet cell numbers were unaffected in
Nlrx1DIEC mice (Figures 1G, S1B, and S1C), although analysis
of Muc2 expression by qPCR revealed increased expression in
Nlrx1DIEC mice (Figure 1H). Together, these results show that
deletion of Nlrx1 in IECs does not significantly alter intestinal
architecture.
Expression of Nlrx1 in the Intestinal Epithelium Protects
against Colitis-Associated Tumorigenesis
We previously reported that whole-body deletion of Nlrx1 exac-
erbated colitis-associated tumorigenesis in the AOM/DSS
model (Soares et al., 2014), but whether this effect was epithe-
lium-intrinsic or due to increased inflammation was not ad-
dressed. Nlrx1fl/fl and Nlrx1DIEC mice received an intraperitoneal
injection of AOM (10 mg/kg) followed by three cycles of DSS
(2.5% in drinking water). In both male and female cohorts of
mice receiving AOM/DSS treatment, animals lost weight during
DSS cycles, which they recovered during the intercycles (Fig-
ure 2A). A trend toward increased weight loss in Nlrx1fl/fl mice
as compared to Nlrx1DIEC mice was observed. Colon short-
ening, an indication of intestinal inflammation, was observed
in both Nlrx1fl/fl and Nlrx1DIEC mice, although it appeared to
be slightly more pronounced in Nlrx1fl/fl mice (Figure 2B). More-
over, histological analysis of colon sections showed no signifi-
cant difference overall between Nlrx1fl/fl and Nlrx1DIEC mice with
regards to inflammation-associated parameters (Figure 2C). In
particular, sub-mucosal edema, tissue damage, polymorpho-
nuclear (PMN) infiltration and hyperplasia were similar between
both groups of mice. However, analysis of tumor burden
showed that AOM-DSS treated Nlrx1DIEC mice developed
approximately twice as many tumors as Nlrx1fl/fl mice (Fig-
ure 2D) and histopathological scoring of these tumors revealed
an increased number of adenomas in Nlrx1DIEC mice (Figures
2E and 2F).
The above results suggest that the impact of Nlrx1 deficiency
on tumorigenesis is epithelial-intrinsic and not driven by changesReports 14, 2576–2586, March 22, 2016 ª2016 The Authors 2577
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Figure 1. Generation and Analysis of Mice
Lacking Nlrx1 in the Intestinal Epithelium
(A) Western blot analysis of NLRX1 and Tubulin
(loading control) in spleen, isolated IEC fraction, and
intestinal mucosa depleted of IECs from Nlrx1/
(KO), WT mice, Nlrx1fl/fl (fl/fl), and Nlrx1 DIEC (DIEC)
mice.
(B–H) Colonic tissue was collected from Nlrx1fl/fl and
Nlrx1 DIEC (IEC-KO) mice and processed for H&E
staining (B), IHC using anti-Ki-67 antibody (C), qPCR
for Ki-67, Cyclin D1, and Cyclin B1 (D), Chga, Gcg,
and Cck (F), or Muc2 (H), immunofluorescence using
anti-chromogranin A (Chga) antibody (E), or AB-PAS
staining (G). For qPCR data, each point represents the
average value for one mouse obtained as a technical
triplicate. The images presented in (B), (C), and (E) are
representative of data analyzed on n R 4 mice. *p <
0.05 and other comparisons showed no statistical
difference.in the inflammatory environment. In agreement with a cancer
cell-intrinsic role of NLRX1, publically available data show that
expression of NLRX1 is lower in tumors than the normal corre-
sponding tissue in human cancers, including bladder, cervical,
esophageal, colon, and skin cancers (Figure S2A). Moreover,
analysis of two large data sets of colorectal cancer demon-
strated that NLRX1 expression was significantly reduced in
colon adenocarcinoma or colon mucinous adenocarcinoma as
compared to normal colon (Figure S2B). Finally, analysis of
1,010 human cancer cell lines (from the Cancer Cell Line Ency-
clopedia) showed that the cell line with the lowest expression2578 Cell Reports 14, 2576–2586, March 22, 2016 ª2016 The Authorsof NLRX1 was NCI-H716, which is derived
from a colon adenocarcinoma (Figure S2C).
Thus, available data from human cancer and
cancer cell lines indicate that NLRX1
expression is reduced in multiple cancers
and in particular in colon cancer.
Mutations in the Adenomatous polyposis
coli (APC) gene are found in sporadic colon
cancers in humans (Raskov et al., 2014)
and result in uncontrolled Wnt signaling
and proliferation of IECs. Mice harboring
the Apcmin mutation develop spontaneous
tumors in the small intestine and in the colon
(Su et al., 1992). Nlrx1-deficient mice were
crossedwithmice carrying theApcmin muta-
tion. Interestingly, Apcmin/+ Nlrx1/ mice
had a significantly reduced lifespan and
had to be euthanized at age 101.1 ±
8.38 days as compared to littermate
Apcmin/+ Nlrx1+/+ mice that survived until
day 132.5 ± 6.39 (Figures 3A and 3B). More-
over, Apcmin/+ Nlrx1/ mice had more
colonic tumors and those were larger than
the ones observed in Apcmin/+ Nlrx1+/+
mice (Figures 3C and 3D). Thus, NLRX1 pro-
tects against tumorigenesis induced by dys-
regulation of the Apc/Wnt signaling axis.Together, these results suggest that NLRX1 acts in an epithe-
lial-intrinsic manner to suppress colorectal tumorigenesis.
Epithelial-Specific Deletion of Nlrx1 Does Not Affect
Peak Tissue Damage Induced by DSS, but Potentiates
Expression of Late Tissue Healing Factors TNFa
and TGFb
In order to better understand how IEC-specific deletion of Nlrx1
contributes to tumorigenesis susceptibility in the colitis-associ-
ated AOM/DSS model, DSS-induced colitis was analyzed in
Nlrx1fl/fl and Nlrx1DIEC mice. Following treatment with 2.5%
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Figure 2. Expression of Nlrx1 in the Intestinal Epithelium Protects against Colitis-Associated Tumorigenesis
Two independent studies were performed in Nlrx1fl/fl and Nlrx1 DIEC mice to analyze the effect of AOM/DSS on tumorigenesis. Cohorts #1 and #2 were littermate
females and males, respectively, either left untreated (nR 3) or receiving AOM/DSS treatment (nR 7).
(A) Weight curves.
(B) Measurement of colon length.
(C) Histopathological evaluation of inflammation-associated parameters.
(D and E) Breakdown of the tumor number per size (diameter) (D) and by grade (E).
(F) Representativemicrographs showing polyps in colons fromAOM/DSS-treatedmice (aberrant crypt foci, ACF and high grade dysplasia, HGD) (non-significant,
NS) (*p < 0.05 and **p < 0.01).
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Figure 3. Nlrx1 Protects against Tumorigen-
esis in Apcmin/+ Mice
Analysis of Apcmin/+ Nlrx1+/+ (n = 6) versus Apcmin/+
Nlrx1/ mice (n = 12).
(A) Survival curve.
(B) Age in days at sacrifice. Tumors were analyzed
for animals sacrificed between days 100–150.
(C) Total number of colonic tumors per mouse.
(D) Cumulative tumor size per mouse (*p < 0.05 and
**p < 0.01).DSS in drinking water for 5 days, both groups of mice lost
weight similarly, up to day 7 (i.e., 2 days after removal of
DSS from drinking water) (Figure 4A). From that time point,
both animal groups recovered weight progressively, indicative
of a healing process, but Nlrx1DIEC mice recovered faster during
the d10–d15 period (Figure 4A). Despite this difference in the
recovery from DSS-induced colitis, inflammation appeared to
be comparable between the two groups of mice, as evidenced
by similar colon length at sacrifice (Figure 4B), histology (Fig-
ure 4C), blinded inflammatory scores on colonic sections (Fig-
ure 4D), levels of keratinocyte chemoattractant or CXCL1 in the
serum (Figure S3A), and of secreted IL-1b from intestinal ex-
plants in culture (Figure S3B). Of note, this analysis further
showed that the peak of intestinal erosion and inflammation
was observed at day 7 in both Nlrx1fl/fl and Nlrx1DIEC mice,
which correlates well with the weight loss data (see Figure 4A),
but suggests that the faster recovery of Nlrx1DIEC mice is inde-
pendent from inflammation. Next, we performed qPCR analysis
on colon mucosa samples from DSS-treated Nlrx1fl/fl and
Nlrx1DIEC mice at day 7 and d12. At the peak of tissue damage
(day 7), inflammation-associated genes such as A20, Il10, and
Il6 were transcriptionally upregulated in both groups of mice
and this activation persisted, at least partially up to d12 (Fig-
ures S3C–S3E). Although we noted a trend for increased upre-
gulation of Il6 at day 7 and d12 in Nlrx1DIEC mice as compared
to Nlrx1fl/fl mice, this effect was not significant. Moreover, Il22
and Il22ra1 were transiently upregulated at day 7, but this in-
duction was similar between Nlrx1fl/fl and Nlrx1DIEC mice (Fig-
ures S3F and S3G). Interestingly, while Tnf, Egf, and Tgfb1
were not transcriptionally upregulated at day 7 in either group
of mice, we observed a delayed upregulation of these genes2580 Cell Reports 14, 2576–2586, March 22, 2016 ª2016 The Authorsat d12, and this upregulation was signifi-
cantly more robust in Nlrx1DIEC mice as
compared to Nlrx1fl/fl mice (Figures 4E–
4G). Previous work demonstrated that mi-
crobial products, in synergy with Notch
signaling, could potentiate Tnf expression
in the intestine (Hu et al., 2008). Interest-
ingly, Notch signaling was activated early
(day 7) during colitis as evidenced by the
upregulation of the Notch target Hey1,
and this induction was significantly more
pronounced in Nlrx1DIEC mice than Nlrx1fl/fl
mice (Figure S3H). At d12, Notch signaling
was still active since expression of Atoh1,
which is inhibited by Notch, was moreblunted in Nlrx1DIEC mice than Nlrx1fl/fl mice (Figure S3I).
Thus, early upregulation of Notch signaling could account, at
least in part, for the increased upregulation of Tnf observed in
Nlrx1DIEC mice during colitis.
TNF, EGF, and TGFb have well-characterized roles in promot-
ing the healing of the intestinal epithelium following injury (Lep-
pkes et al., 2014; Sturm and Dignass, 2008). In particular, TNF
stimulates the proliferation of IEC, TGFb potentiates their migra-
tion, and EGF promotes both. Thus, these results suggest
that Nlrx1 deficiency in IEC does not impact the initial wave of in-
duction of inflammatorymediators, which likely originate from im-
mune cells of the lamina propria, but upregulates second-wave
mediators involved in tissue healing such as TNF, EGF, andTGFb.
Increased Epithelial Proliferation in Nlrx1DIEC Mice
during Epithelial Regeneration
Treatment with DSS results in a massive epithelial erosion
and healing requires upregulation of IEC proliferation and
migration. Because we observed increased expression of
TNF in Nlrx1DIEC mice during the regeneration phase following
DSS treatment (see above), we aimed to analyze epithelial
proliferation.
Immunohistochemistry (IHC) staining using anti-Ki-67, a
marker of cellular proliferation, revealed that an increased num-
ber of epithelial cells were proliferative in the crypts of Nlrx1DIEC
mice as compared to Nlrx1fl/fl mice at d12 and d20 post-DSS
treatment (Figures 5A–5C). It must be noted that at the peak of
DSS-induced tissue damage (day 7), the epithelium was too
eroded to perform analysis of Ki-67. In the AOM/DSS-treated an-
imals analyzed above (see Figure 2), which were sacrificed at
d20 of the third DSS cycle, a similar increase in the number of
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Figure 4. Epithelial-Specific Deletion of
Nlrx1 Does Not Affect Peak Tissue Damage
Induced by DSS, but Potentiates Expression
of Late Tissue Healing Factors TNFa
and TGFb
Nlrx1fl/fl and Nlrx1 DIEC mice were challenged with
2.5% DSS for 5 days in drinking water.
(A) Weight curves.
(B) Measurement of colon length of animals
sacrificed at day 7 (5 days DSS/2 days recovery in
normal water), d12 (5 days DSS/7 days recovery),
and d20 (5 days DSS/15 days recovery).
(C) Representative H&E micrographs of colons of
animals unchallenged (CTR) or challenged with
DSS at day 7, d12, and d20.
(D) Histopathological evaluation of inflammation-
associated parameters. The numbers on the right
side of the image: 1, total area affected; 2,
destruction of mucosal architecture; 3, % severe
destruction; 4, degree of cellular infiltration; 5, %
severely affected; 6, muscle thickening; 7, crypt
abscess; and 8, goblet cell depletion.
(E–G) qPCR analysis of Tnf (E), Egf (F), and Tgfb1
(G) in colonic tissues of animals unchallenged
(CTR) or challenged with DSS at day 7, d12, and
d20. Each point represents the average value for
one mouse obtained as a technical triplicate. (*p <
0.05 and **p < 0.01). (non-significant, NS).Ki-67+ cells was observed in the crypts of Nlrx1DIEC mice as
compared to Nlrx1fl/fl mice (Figure 5D).
In resting conditions, epithelial cell death must approximately
be equal to proliferation in order to keep colonic crypt length
constant. Because we previously showed that NLRX1 controls
apoptotic cell death, we sought to determine if the more robust
proliferation observed in DSS-treated Nlrx1DIEC IECs was the
result of increased apoptosis. IHC analysis of apoptosis using
an antibody against the cleaved form of caspase-3 showed an
increase in apoptosis in the colonic crypts of d12 DSS-treated
mice as compared to unchallenged animals, but this increase
was similar between Nlrx1fl/fl and Nlrx1DIEC mice (Figures 5E
and 5F), thus ruling out the possibility that increased proliferation
in DSS-treated Nlrx1DIEC mice was a compensation mechanism
for enhanced apoptotic cell death. Together, these results show
that NLRX1 negatively regulates IEC proliferation during the
epithelial regeneration phase following intestinal injury.Cell Reports 14, 2576–2586Expression of NLRX1 Inhibits TNF-
Mediated Proliferation and
Signaling in Primary Intestinal
Organoids
In order to gain insights into the mecha-
nism through which epithelial-intrinsic
expression of NLRX1 inhibits epithelial
proliferation during the regeneration
phase post-DSS, we isolated intestinal
crypts and cultured primary intestinal
organoids from Nlrx1fl/fl and Nlrx1DIEC
mice in Matrigel, as previously de-
scribed (Sato et al., 2009). Since weobserved increased expression of TNF in the colons of
Nlrx1DIEC mice as compared to Nlrx1fl/fl mice during the
epithelial regeneration phase (see Figure 4), we hypothesized
that TNF could contribute to the hyper-proliferative response
observed in Nlrx1DIEC mice recovering from DSS. TNF stimu-
lation for 24 hr of freshly passaged organoids from Nlrx1fl/fl
mice resulted in a modest non-significant increase in the
diameter of the organoids (Figures 6A and 6B). In contrast,
TNF stimulation more than doubled the surface of organoids
from Nlrx1DIEC mice (Figures 6A and 6B), and those also had
more numerous and longer digitations, showing that these
structures displayed increased crypt growth. Next, TNF-stim-
ulated organoids were pulsed with EdU, which incorporates
into proliferative cells, and analyzed by flow cytometry.
Interestingly, organoids from Nlrx1DIEC mice displayed more
EdU+ cells than those from Nlrx1fl/fl mice (Figures 6C and
6D), thus showing that the increase in organoid size following, March 22, 2016 ª2016 The Authors 2581
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Figure 5. Increased Epithelial Proliferation
in Nlrx1DIEC Mice during Epithelial Regener-
ation
(A) IHC using anti-Ki-67 antibody of colonic sec-
tions of Nlrx1fl/fl and Nlrx1 DIEC mice unchallenged
(CTR) or challenged with 2.5% DSS at d12 (5 days
DSS/7 days recovery).
(B–D) Quantification of the average proportion of
the crypt length that is Ki-67+ at post-DSS d12 (B),
d20 (C), or animals challenged with AOM/DSS (D).
Each point represents the quantification of n R
100 crypts of one animal.
(E and F) Representative IHC micrographs (E)
and quantification (F) or colonic sections at d12
post-DSS using an antibody against the cleaved
caspase-3.TNF stimulation was caused, at least in part, by hyper-
proliferation.
Intestinal organoids grow from rapidly dividing pluripotent in-
testinal stem cells (ISCs) that are found at the bottom of the
crypts and express themarker Lgr5 (Barker et al., 2007). Another
ISC population, likely acting as a reserve ISC, expresses Bmi1
(Sangiorgi and Capecchi, 2008; Tian et al., 2011). Cells leaving
the ISC niche lose expression of the Lgr5 and Bmi1 markers
and form the transit-amplifying (TA) zone, in which cells remain
highly proliferative and still express numerous ISC markers, but
progressively differentiate into specific IEC populations. qPCR
analysis revealed that stimulation with TNF resulted in a modest
increase in the expression of Lgr5 and Bmi1 in intestinal organo-
ids from bothNlrx1DIEC andNlrx1fl/fl mice; however, this increase
was not significantly different between the two groups of organo-
ids (Figures S4A and S4B). Next, we analyzed the expression of
Olfm4, an ISCmarker that, in contrast to Bmi1 and Lgr5, remains2582 Cell Reports 14, 2576–2586, March 22, 2016 ª2016 The Authorsexpressed in the TA zone (Itzkovitz et al.,
2012). Interestingly, we observed stron-
ger upregulation of Olfm4 in organoids
from Nlrx1DIEC than those from Nlrx1fl/fl
mice following TNF stimulation (Fig-
ure 6E), suggesting that NLRX1 specif-
ically represses proliferation of cells in
the TA zone, rather than cells in the ISC
niche.
Uncontrolled proliferation of cells in the
ISC niche or the TA zone can drive tumor-
igenesis. It was shown that the transcrip-
tion factorMyb, which is highly expressed
in ISCs (Mun˜oz et al., 2012), was required
for proliferation in colonic crypts (Mala-
terre et al., 2007) and Myb activation
results in colon tumorigenesis in mice
(Malaterre et al., 2015). Strikingly, TNF
stimulation resulted in only a transient up-
regulation ofMyb expression in organoids
fromNlrx1fl/fl mice, while this upregulation
persisted in those from Nlrx1DIEC mice
(Figure 6F). Thus, dysregulated expres-
sion of Myb in the colonic crypts ofNlrx1DIEC mice during epithelial restitution following injury could
contribute to the exacerbated tumorigenesis observed in these
mice in the AOM/DSS model.
We have demonstrated above that epithelial regeneration
following DSS-induced injury resulted in exacerbated expres-
sion of Tnf, Egf, and Tgfb1 in Nlrx1DIEC mice as compared to
Nlrx1fl/fl mice, suggesting that these factors could be ex-
pressed by the intestinal epithelium itself, since non-IECs in
both groups of mice are WT. In support for this, we observed
that stimulation of organoids from Nlrx1DIEC and Nlrx1fl/fl mice
with TNF resulted in potent transcriptional upregulation of both
Tnf and Tgfb1 (Figures 6G and 6H), as well as a more modest
induction of Egf (Figure S4C). In contrast, Il6 transcript was un-
detectable in these conditions (data not shown). Therefore,
these data support the notion that Tnf, Tgfb1, and Egf can
be expressed through paracrine regulation by the intestinal
epithelium.
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Figure 6. Expression of NLRX1 Inhibits TNF-
Mediated Proliferation and Signalization in
Primary Intestinal Organoids
(A and B) Representative bright field micrographs
(A) and quantification of the surface (B) of intestinal
organoids derived from Nlrx1fl/fl (fl/fl) and Nlrx1 DIEC
(IEC-KO) mice in normal growth media supple-
mented or not with TNF at 10 ng/ml for 24 hr. For
quantifications, each point represents the average
surface area of all the organoids found in one indi-
vidual culture well. The results are representative of
two independent experiments.
(C and D) Analysis by flow cytometry (C) and
quantification of the average mean fluorescence
intensity (MFI) (D) of EdU incorporation in fl/fl and
IEC-KO organoids stimulated or not with TNF at
10 ng/ml for 4 hr. The results are representative of
three independent experiments.
(E–H) qPCR analysis of the expression of Olfm4 (E),
Myb (F), Tnf (G), or Tgfb1 (H) in fl/fl and IEC-KO
organoids stimulated or not with TNF at 10 ng/ml for
4 or 8 hr. Each point represents the average value
for technical triplicate of individual organoid cul-
tures derived from different mice.
(I) Western blot analysis of fl/fl and IEC-KO orga-
noids stimulated or not with TNF at 10 ng/ml for 15
to 60 min. The blots are representative of two in-
dependent experiments (*p < 0.05; **p < 0.01; ***p <
0.001; and ****p < 0.0001) (non-significant, NS).In order to better understand the mechanism through which
TNF triggered a hyper-proliferative response in organoids from
Nlrx1DIEC mice, we analyzed by western blotting the activation
of Akt, a protein that plays a central role in the regulation of
epithelial cell proliferation (Lee et al., 2010) and whose dysregu-
lation is strongly associated with colorectal cancer (Agarwal
et al., 2013; Leystra et al., 2012). TNF stimulation resulted in rapid
upregulation of Akt phosphorylation in both groups of organoids;
however, the effect was stronger and more sustained in organo-
ids from Nlrx1DIEC mice than those from Nlrx1fl/fl mice (Figure 6I).
Finally, we analyzed NF-kB signaling, since this pathway is also
critical for the control of IEC proliferation and intestinal tumori-
genesis (Myant et al., 2013; Steinbrecher et al., 2008). Similar
to Akt activation, we observed that TNF stimulation triggered
degradation of the inhibitory molecule Ikba, which indicates
NF-kB activation, in both groups of organoids, but the effect
was again more sustained in organoids from Nlrx1DIEC mice
than those from Nlrx1fl/fl mice (Figure 6I). Together, these results
indicate that TNF-mediated hyper-proliferative response in orga-Cell Reports 14, 2576–2586noids from Nlrx1DIEC mice was associated
with exacerbated activation of the Akt and
NF-kB signaling pathways and upregula-
tion of the transcription factor Myb.
DISCUSSION
Chronic injury of the intestinal mucosa can
favor the development of colorectal
cancer. This is highlighted by the fact
that inflammatory bowel disease confersincreased risk of developing gastrointestinal neoplasia in hu-
mans. Similarly, repeated exposure to the epithelial irritant DSS
greatly accelerates tumor formation in the AOM/DSS model in
mice (Rosenberg et al., 2009). It is clear that inflammation plays
a critical role in this effect, and inflammation-associated cyto-
kines such as IL-6 are known to contribute to the pathogenesis
of colorectal cancer (Waldner and Neurath, 2014). However, it
is less appreciated that epithelial regeneration and wound repair
pathways, which are triggered as a direct consequence of
mucosal injury and are amplified by inflammatory mediators,
likely play central roles in colitis-associated intestinal tumorigen-
esis. Indeed, these important processes rely on cellular prolifer-
ation and migration and on signaling pathways dependent on
NF-kB, Akt/PI3K, and Wnt/b-catenin, all of which being critical
actors of colorectal cancer pathogenesis. Because inflammation
and epithelial repair pathways are tightly interconnected and are
spatially and temporally coordinated, it is difficult to determine
what aspects of inflammation (i.e., recruitment of immune cells,
upregulation of phagocytosis, secretion of inflammatory or, March 22, 2016 ª2016 The Authors 2583
immune defensemediators, microbiota dysbiosis, and upregula-
tion of epithelial repair) have the most important impact on
tumorigenesis. Oneway to approach this question and to identify
key molecular pathways linking specific arms of inflammation to
tumorigenesis is to perform analysis of mice with tissue-specific
gene deletion. Here, by using mice harboring a deletion of Nlrx1
only in IECs, we identified an epithelial-intrinsic role for this NLR
molecule in the control of IEC proliferation during the epithelial
regeneration phase following DSS treatment. Our data suggest
that Nlrx1 deletion exacerbates cellular responses to TNF, which
could generate a paracrine or autocrine amplification loop in
IECs by triggering Tnf expression. This effect might also amplify
the expression of other wound healing genes, such as Tgfb1 and
Egf, as suggested by our results in intestinal organoids. Thus, our
data suggest that, by restricting the activation of Akt and NF-kB
in IECs in response to TNF stimulation, NLRX1 tones down the
effect of TNF on the proliferation of TA cells in the intestinal crypt,
providing a protection against colitis-associated tumorigenesis.
It is possible that a similar mechanism underlies the protective
role of NLRX1 against tumorigenesis in mice carrying the Apcmin
mutation, since increased mucosal expression of Tnf was
observed in these mice and correlated with tumor formation
(McClellan et al., 2012).
Our previous results demonstrated that full-body deletion of
Nlrx1 resulted in increased inflammation following DSS treat-
ment (Soares et al., 2014), which is in line with other studies
showing an inhibitory effect of NLRX1 on inflammation (Allen
et al., 2011; Xia et al., 2011; Eitas et al., 2014; Kang et al.,
2015). Although this effect is likely immune cell-intrinsic, the un-
derlyingmechanism is not clearly elucidated, nor are the immune
cell subsets identified that are undergoing uncontrolled activa-
tion in Nlrx1-deficient mice. Nevertheless, these observations,
together with the results of the present study, suggest that
NLRX1 might mitigate colitis-associated tumorigenesis at two
levels: (1) by downregulating inflammation and (2) by inhibiting
pro-proliferative responses in the intestinal epithelium in
response to inflammatory and pro-regeneration cues.
Our data show that, in intestinal organoids, NLRX1 diminishes
TNF-induced activation of both Akt- and NF-kB-dependent
pathways. Since Akt was shown to be essential for TNF-medi-
ated activation of NF-kB (Ozes et al., 1999), it is likely that the pri-
mary effect of NLRX1 is at the level of Akt signaling. Alternatively,
NLRX1 could regulate a step or an event that controls both path-
ways, such asmitochondrial ROS levels or expression of TNF re-
ceptors. Future studies will aim at identifying the molecular
mechanism by which NLRX1 mitigates Akt and NF-kB signaling
in response to TNF stimulation in IECs.
Overall, our study identifies an epithelial-intrinsic role for
NLRX1 in the control of colon tumorigenesis through the modu-
lation of epithelial proliferation following injury. Experiments in
primary intestinal organoids further revealed that NLRX1 directly
impacted Akt and NF-kB pathways, expression of the prolifera-
tion-associated transcription factor Myb, and proliferation of
crypt TA cells in response to TNF. Identifying the mechanism
through which NLRX1 controls these pathways will allow the
designing of novel therapeutic strategies aimed at regulating hy-
per-proliferative responses in colon cancer without having to
suppress inflammatory cytokine networks.2584 Cell Reports 14, 2576–2586, March 22, 2016 ª2016 The AuthorEXPERIMENTAL PROCEDURES
Animals
All mice were bred and housed at the Division of Clinical Medicine (DCM) of the
University of Toronto and experiments were performed according to guide-
lines of the DCMand following protocols approved by the University of Toronto
Committee on Use and Care of Animals. Mice were kept in specific pathogen-
free conditions with periodic testing for murine norovirus and used for exper-
iments at age 6–10 weeks except otherwise indicated. All experiments were
performed using littermate animals that were separated at weaning. Nlrx1/
mice have been described previously (Soares et al., 2013).
Generation of IEC-Specific NLRX1-Deficient Mice
NLRX1-deficient mice (Nlrx1DIEC) were generated by crossing Nlrx1fl/fl mice
(Soares et al., 2013) with transgenic mice B6.SJL-Tg(Vil-cre)997Gum/J (Jack-
son Laboratories), which express Cre recombinase under the control of the
mouse villin promoter. The following PCR primers (50–30) were used to geno-
type WT, floxed, and Nlrx1DIEC mice: primer 1- (CCA TTT GCC AAT CCC
ACT CAC), primer 2 (ACC AAG AAC CTA ACC CAC GGT C), primer 3 (TTG
CCA GCC ATC TGT TGT TTG), oIMR1878 (GTG TGG GAC AGA GAA CAA
ACC), and oIMR1879 (ACA TCT TCA GGT TCT GCG GG).
Induction of DSS-Induced Colitis
Colitis was induced with 2.5% (w/v) DSS (MP Biomedicals) dissolved in sterile,
distilled water for experimental days 5, followed by normal drinking water until
the end of the experiment.
Colitis-Associated Colorectal Cancer
Mice were injected intraperitoneally with 10 mg/kg AOM (Sigma-Aldrich). After
5 days, 2.5% DSS was given in drinking water over 5 days, followed by regular
drinking water for 2 weeks. This cycle was repeated three times, and mice
were sacrificed 2 weeks after the last DSS cycle. The experiments were per-
formed with at least 4–8 mice in each AOM-treated condition.
Reagents and Antibodies
AOM (Sigma-Aldrich, A5486). DSS (MP Biomedicals, 160110). The following
antibodies were used for protein detection: rabbit polyclonal AKT rabbit poly-
clonal (Cell Signaling Technology, 9272S), rabbit polyclonal Phospho-AKT
(Ser473) (Cell Signaling Technology, 9271S), rabbit polyclonal anti-cleaved
caspase-3 (Asp175) (Cell Signaling Technology, 9661S), rabbit anti-chromog-
ranin A (Abcam, ab15160), rabbit anti-Muc2 (H300) (Santa Cruz, sc-15334)
mouse monoclonal anti-tubulin (Sigma-Aldrich, T9026), rabbit polyclonal
anti-Ki-67 (D3B5) (Cell Signaling Technology, 12202), mouse monoclonal
anti-NLRX1 (Millipore, 04-146) and rabbit monoclonal anti-IkB-a (E130)
(Abcam, ab32518), goat anti-rabbit (ThermoScientific / Molecular Probes,
A-21245), AB solution (Sigma-Aldrich, B8438), Periodic Acid- Schiff (PAS) kit
(Sigma-Aldrich, 395B), Alexa Fluor 647 donkey anti-rabbit (Life Technologies,
A31573), and Click-iT EdU Flow Cytometry Assay Kit (Life Technologies,
C10419).
Statistical Analysis
Prism software was used to plot data and determine statistical significance us-
ing a Student’s t test (for two groups) or ANOVA for data sets with three ormore
sets of data to analyze. Data are presented as means ± SEM. A p value of
<0.05 was considered to be statistically significant.
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